TY - JOUR
T1 - Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder
T2 - A prospective multicenter randomized double-blind placebo-controlled trial
AU - Carmi, Lior
AU - Tendler, Aron
AU - Bystritsky, Alexander
AU - Hollander, Eric
AU - Blumberger, Daniel M.
AU - Daskalakis, Jeff
AU - Ward, Herbert
AU - Lapidus, Kyle
AU - Goodman, Wayne
AU - Casuto, Leah
AU - Feifel, David
AU - Barnea-Ygael, Noam
AU - Roth, Yiftach
AU - Zangen, Abraham
AU - Zohar, Joseph
N1 - Funding Information:
Dr. Carmi has received research and travel support from Brainsway. Dr. Tendler serves as the chief medical officer of and has a financial interest in Brainsway, and he has ownership interest in Advanced Mental Health Care, Inc. Dr. Bystritsky is an investigator on and receives grant support for several clinical trials by Brainsway. Dr. Hollander receives grant support from Brainsway. Dr. Blumberger has received research support from the Canadian Institutes of Health Research, NIH, Brain Canada, the Patient-Centered Outcomes Research Institute, the Weston Brain Institute, and the Temerty Family through the Centre for Addiction and Mental Health Foundation and the Campbell Research Institute; he receives research support and in-kind equipment support for an investigator-initiated study from Brainsway and is the site principal investigator for three sponsor-initiated studies for Brainsway; he receives in-kind equipment support from Magventure for an investigator-initiated study; he has received medication supplies for an investigator-initiated trial from Indivior; and he has participated on an advisory board for Janssen. Dr. Daskalakis has received research and in-kind equipment support for an investigator-initiated study through Brainsway and Magventure; his work was supported by the Ontario Mental Health Foundation, the Canadian Institutes of Health Research, NIMH, and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health Foundation and the Campbell Institute. Dr. Lapidus has received research support from the Brain and Behavior Research Foundation, the Education and Research Foundation for Nuclear Medicine and Molecular Imaging, the Le Foundation, NIMH, and the Simons Foundation; he has received devices, meals, travel support, and research support from Brainsway, Halo Neuroscience, Medtronic, Neuronetics, and Roche; he has served as a consultant for Cipla, FCB Health, LCN Consulting, SmartAnalyst, and Third Bridge; he founded New York Neuromodulation Medical and Sol2rise and has ownership interest in Victory Recovery Partners, in Halo Neuroscience (for whom he also serves on the advisory board), and Validose (for whom he also serves as chief medical officer); and he is named on a patent application for an intranasal medication administration device for Validose, whichdevelopsproductsrelatedtothispatent.Dr.Goodmanhasservedas a consultant for Biohaven Pharma. Dr. Feifel has received advisory board travel support from Brainsway. Dr. Roth is a key inventor of deep TMS and has a financial interest in Brainsway. Prof. Zangen has a financial interest in Brainsway. Dr. Zohar has received grant and research support from Brainsway, Lundbeck, and Servier, and he has served as a consultant, on advisoryboards,oronspeakersbureausforAbbott,Actelion,Brainsway,Eli Lilly, Lundbeck, Pfizer, Roche, Servier, and Sun Pharma. The other authors report no financial relationships with commercial interests.
PY - 2019
Y1 - 2019
N2 - Objective: Obsessive-compulsive disorder (OCD) is a chronic and disabling condition that often responds unsatisfactorily to pharmacological and psychological treatments. Converging evidence suggests a dysfunction of the cortical-striatalthalamic-cortical circuit in OCD, and a previous feasibility study indicated beneficial effects of deep transcranial magnetic stimulation (dTMS) targeting the medial prefrontal cortex and the anterior cingulate cortex. The authors examined the therapeutic effect of dTMS in a multicenter double-blind sham-controlled study. Methods: At 11 centers, 99 OCD patients were randomly allocated to treatment with either high-frequency (20 Hz) or sham dTMS and received daily treatments following individualized symptom provocation, for 6 weeks. Clinical response to treatment was determined using the Yale-Brown Obsessive Compulsive Scale (YBOCS), and the primary efficacy endpoint was the change in score from baseline to posttreatment assessment. Additional measures were response rates (defined as a reduction of $30% in YBOCS score) at the posttreatment assessment and after another month of follow-up. Results: Eighty-nine percent of the active treatment group and 96% of the sham treatment group completed the study. The reduction in YBOCS score among patients who received active dTMS treatment was significantly greater than among patients who received sham treatment (reductions of 6.0 points and 3.3 points, respectively), with response rates of 38.1% and 11.1%, respectively. At the 1-month followup, the response rates were 45.2% in the active treatment group and 17.8% in the sham treatment group. Significant differences between the groups were maintained at follow-up. Conclusions: High-frequency dTMS over the medial prefrontal cortex and anterior cingulate cortex significantly improved OCD symptoms and may be considered as a potential intervention for patients who do not respond adequately to pharmacological and psychological interventions.
AB - Objective: Obsessive-compulsive disorder (OCD) is a chronic and disabling condition that often responds unsatisfactorily to pharmacological and psychological treatments. Converging evidence suggests a dysfunction of the cortical-striatalthalamic-cortical circuit in OCD, and a previous feasibility study indicated beneficial effects of deep transcranial magnetic stimulation (dTMS) targeting the medial prefrontal cortex and the anterior cingulate cortex. The authors examined the therapeutic effect of dTMS in a multicenter double-blind sham-controlled study. Methods: At 11 centers, 99 OCD patients were randomly allocated to treatment with either high-frequency (20 Hz) or sham dTMS and received daily treatments following individualized symptom provocation, for 6 weeks. Clinical response to treatment was determined using the Yale-Brown Obsessive Compulsive Scale (YBOCS), and the primary efficacy endpoint was the change in score from baseline to posttreatment assessment. Additional measures were response rates (defined as a reduction of $30% in YBOCS score) at the posttreatment assessment and after another month of follow-up. Results: Eighty-nine percent of the active treatment group and 96% of the sham treatment group completed the study. The reduction in YBOCS score among patients who received active dTMS treatment was significantly greater than among patients who received sham treatment (reductions of 6.0 points and 3.3 points, respectively), with response rates of 38.1% and 11.1%, respectively. At the 1-month followup, the response rates were 45.2% in the active treatment group and 17.8% in the sham treatment group. Significant differences between the groups were maintained at follow-up. Conclusions: High-frequency dTMS over the medial prefrontal cortex and anterior cingulate cortex significantly improved OCD symptoms and may be considered as a potential intervention for patients who do not respond adequately to pharmacological and psychological interventions.
UR - http://www.scopus.com/inward/record.url?scp=85074379975&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074379975&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2019.18101180
DO - 10.1176/appi.ajp.2019.18101180
M3 - Article
C2 - 31109199
AN - SCOPUS:85074379975
VL - 176
SP - 931
EP - 938
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
SN - 0002-953X
IS - 11
ER -